LONDON--(BUSINESS WIRE)-- Pricing and reimbursement have important roles in evaluation of sales effectiveness of a pharmaceutical product. Failure to comply with pricing levels and reimbursement status can provoke lost profit or restricted therapy choice for both patients and clinicians. In terms of current unfavorable economic conditions pricing controls are used by health payers as a mean to limit drug expenditure. Fixed generic price reductions, reference pricing schemes, companies profits limitations and fixed wholesale and pharmacy mark-ups are some of the common methods utilized by national pricing authorities to arrive at agreed pharmaceutical prices. Another critical factor in price setting is gaining of reimbursement status. Research report The Worldwide Guide to Pricing & Reimbursement designed by Espicom Business Intelligence examines the present state of pricing and reimbursement in 58 leading and emerging economies. It scrutinizes the policies and practices having influence on the pharmaceutical industrys operating environment. The report describes how pricing and reimbursement vary in different regions; each country-wise market analysis includes a comprehensive review of drug pricing, reference pricing, controls, policy, regulation and reimbursement systems as well as influencing factors such as procurement and formulary. Countries covered in the report: Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, the USA, … Continue reading →